Antiarrhythmic effect of L-propionylcarnitine in isolated cardiac preparations.
The effects of L-propionylcarnitine on reperfusion-induced ventricular arrhythmias were studied in isolated hearts from spontaneously hypertensive rats. During reperfusion, 60% (n = 15) of the hearts from control spontaneously hypertensive rats hearts developed irreversible ventricular fibrillation. In contrast, irreversible ventricular fibrillation did not occur in hearts from normotensive Wistar Kyoto rats (n = 11, p less than 0.01). In a second group of spontaneously hypertensive rats, the addition of 10(-6) M L-propionylcarnitine to the medium during ischemia and reperfusion reduced the incidence of irreversible ventricular fibrillation to 14% (n = 14, p less than 0.05 versus control spontaneously hypertensive rats, NS versus Wistar Kyoto rats). Concentrations of L-propionylcarnitine from 10(-6) to 10(-2) M were tested on isolated guinea pig papillary muscles using microelectrodes. Resting potential, action potential amplitude, action potential duration and active tension were not modified by L-propionylcarnitine; and 10(-3) M L-propionylcarnitine did not influence the oscillatory afterpotentials induced by digitalis. We conclude that reperfusion ventricular arrhythmias are more severe in spontaneously hypertensive rats than in Wistar Kyoto rats and that the antiarrhythmic effect of L-propionylcarnitine in spontaneously hypertensive rats is mediated by myocardial protection from damage induced by reperfusion.
Carbonin
P U
PU
Cattedra di Gerontologia, Università Cattolica, Rome, Italy.
Ramacci
M T
MT
Pahor
M
M
Di Gennaro
M
M
Gambassi
G
G
Lo Giudice
P
P
Sgadari
A
A
Pacifici
L
L
D000818:Animals; D000889:Anti-Arrhythmia Agents; D002331:Carnitine / Q000031:analogs & derivatives* / Q000494:pharmacology; D006168:Guinea Pigs; D008297:Male; D015428:Myocardial Reperfusion Injury / Q000517:prevention & control*; D010210:Papillary Muscles / Q000187:drug effects; D051381:Rats; D011918:Rats, Inbred SHR; D011921:Rats, Inbred WKY; D014693:Ventricular Fibrillation / Q000517:prevention & control*
D000889:Anti-Arrhythmia Agents; C003223:propionylcarnitine; D002331:Carnitine